Stocks / URGN vs USPH

UroGen Pharma Ltd. (URGN) vs U.S. Physical Therapy, Inc. (USPH)

UroGen Pharma Ltd. and U.S. Physical Therapy, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

URGN is the larger company ($1.4B vs $0.9B). On the fundamentals, URGN grows revenue faster (56.2% vs 13.0%); USPH earns a higher net margin (5.1% vs -139.8%); URGN has the stronger return on equity (145.5% vs 8.3%). Over the last five years, URGN returned 85.4% vs -40.8%. On the filings, USPH carries fewer potential red flags (0 vs 5). Full numbers below — the stronger figure on each row is in green.

AI verdict — URGN vs USPH, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 UroGen Pharma Ltd. (URGN)U.S. Physical Therapy, Inc. (USPH)
Market cap$1.4B$0.9B
Revenue (latest FY)$109.79M$780.99M
Net income (latest FY)$-153.49M$39.58M
Revenue growth (5y CAGR)56.2%13.0%
Net margin-139.8%5.1%
Return on equity145.5%8.3%
P/E ratio124.5
Dividend yield2.9%
Profitable years (of last 10)010
Positive free cash flowNoYes

Performance — URGN vs USPH

Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.

 UroGen Pharma Ltd. (URGN)U.S. Physical Therapy, Inc. (USPH)
1-year return106.6%-18.4%
3-year return173.5%-45.3%
5-year return85.4%-40.8%
10-year return19.4%
52-week range$6.92–$32.37$58.19–$93.50

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full URGN vs USPH breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open URGN's full financials →   Open USPH's full financials →

More comparisons

Frequently asked questions

Which is bigger, URGN or USPH?

UroGen Pharma Ltd. is larger by market capitalization — $1.4B versus $0.9B.

Which grows faster, URGN or USPH?

Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus 13.0%/yr, computed from SEC-filed statements.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

URGN fundamentals → · USPH fundamentals → · All 1,500+ companies → · Free screener →